Temsirolimus in women with platinum-refractory/resistant ovarian cancer or advanced/recurrent endometrial carcinoma. A phase II study of the AGO-study group (AGO-GYN8)

设为首页

收藏本站

网站地图 | English | 公务邮箱

About the library

Background
History
Leadership
Organization

Readers' Guide

Opening Hours
Collections
Help Via Email

Publications

Electronic Information Resources

Temsirolimus in women with platinum-refractory/resistant ovarian cancer or advanced/recurrent endometrial carcinoma. A phase II study of the AGO-study group (AGO-GYN8)

详细信息查看全文

作者：Gü ; nter Emons^a ; ^{emons@med.uni-goettingen.de" class="auth_mail" title="E-mail the corresponding author} ; Christian Kurzeder^b ; ^{c.kurzeder@kliniken-essen-mitte.de" class="auth_mail" title="E-mail the corresponding author} ; Barbara Schmalfeldt^c ; ¹ ; ^{b.schmalfeldt@uke.de" class="auth_mail" title="E-mail the corresponding author} ; Petra Neuser^d ; ^{Petra.Neuser@KKS.uni-marburg.de" class="auth_mail" title="E-mail the corresponding author} ; Nikolaus de Gregorio^e ; ^{Nikolaus.deGregorio@uniklinik-ulm.de" class="auth_mail" title="E-mail the corresponding author} ; Jacobus Pfisterer^f ; ² ; ^{jacobus.pfisterer@googlemail.com" class="auth_mail" title="E-mail the corresponding author} ; Tjoung-Won Park-Simon^g ; ^{park-simon.tjoung-won@mh-hannover.de" class="auth_mail" title="E-mail the corresponding author} ; Sven Mahner^h ; ³ ; ^{Sven.Mahner@med.uni-muenchen.de" class="auth_mail" title="E-mail the corresponding author} ; Willibald Schrö ; derⁱ ; ^{prof.schroeder@gynaekologicum-bremen.de" class="auth_mail" title="E-mail the corresponding author} ; Hans-Joachim Lü ; ck^j ; ^{hlueck@goph.de" class="auth_mail" title="E-mail the corresponding author} ; Martin Leonhard Heubner^k ; ^{martin.heubner@uk-essen.de" class="auth_mail" title="E-mail the corresponding author} ; Lars Hanker^l ; ⁴ ; ^{Lars.Hanker@uksh.de" class="auth_mail" title="E-mail the corresponding author} ; Falk Thiel^m ; ⁵ ; ^{Falk.Thiel@af-k.de" class="auth_mail" title="E-mail the corresponding author} ; Felix Hilpertⁿ ; ^{felix.hilpert@gmail.com" class="auth_mail" title="E-mail the corresponding author}
关键词：Ovarian cancer ; Endometrial cancer ; Temsirolimus ; mTOR inhibitor ; Rapalog
刊名：Gynecologic Oncology
出版年：2016
出版时间：March 2016
年：2016
卷：140
期：3
页码：450-456
全文大小：346 K

文摘

class="label">•: Temsirolimus has marginal activity in ovarian and endometrial cancer
class="label">•: Durable disease stabilisation was observed in some patients
class="label">•: Toxicity was acceptable